Literature DB >> 19197941

A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells.

Ludovic Martinet1, Sandrine Fleury-Cappellesso, Mélanie Gadelorge, Gilles Dietrich, Philippe Bourin, Jean-Jacques Fournié, Rémy Poupot.   

Abstract

The physiological functions of human TCRVgamma9Vdelta2(+) gammadelta lymphocytes reactive to non-peptide phosphoantigens contribute to cancer immunosurveillance and immunotherapy. However, their regulation by mesenchymal stem cells (MSC), multipotent and immunomodulatory progenitor cells able to infiltrate tumors, has not been investigated so far. By analyzing freshly isolated TCRVgamma9Vdelta2(+) lymphocytes and primary cell lines stimulated with synthetic phosphoantigen or B-cell lymphoma cell lines in the presence of MSC, we demonstrated that MSC were potent suppressors of gammadelta-cell proliferation, cytokine production and cytolytic responses in vitro. This inhibition was mediated by the COX-2-dependent production of prostaglandin E2 (PGE(2)) and by MSC through EP2 and EP4 inhibitory receptors expressed by Vgamma9Vdelta2 T lymphocytes. COX-2 expression and PGE(2) production by MSC were not constitutive, but were induced by IFN-gamma and TNF-alpha secreted by activated Vgamma9Vdelta2 T cells. This regulatory cross-talk between MSC and Vgamma9Vdelta2 T lymphocytes involving PGE(2) could be of importance for the antitumor and antimicrobial activities of gammadelta T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19197941     DOI: 10.1002/eji.200838812

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  36 in total

1.  Expansion of Th1-like Vγ92T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.

Authors:  T Harada; H Miki; Q Cui; A Oda; R Amachi; J Teramachi; A Bat-Erdene; K Sogabe; M Iwasa; S Fujii; S Nakamura; K Kagawa; S Yoshida; I Endo; K Aihara; S Ozaki; T Matsumoto; M Abe
Journal:  Leukemia       Date:  2016-10-04       Impact factor: 11.528

2.  Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition.

Authors:  Govindaiah Vinukonda; Anna Csiszar; Furong Hu; Krishna Dummula; Nishi Kant Pandey; Muhammad T Zia; Nicholas R Ferreri; Zoltan Ungvari; Edmund F LaGamma; Praveen Ballabh
Journal:  Brain       Date:  2010-05-20       Impact factor: 13.501

3.  Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

Authors:  Daniel Gonnermann; Hans-Heinrich Oberg; Christian Kellner; Matthias Peipp; Susanne Sebens; Dieter Kabelitz; Daniela Wesch
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

Review 4.  How tumors might withstand γδ T-cell attack.

Authors:  Aude-Hélène Capietto; Ludovic Martinet; Jean-Jacques Fournié
Journal:  Cell Mol Life Sci       Date:  2011-05-06       Impact factor: 9.261

Review 5.  Gamma-delta T-cell lymphomas.

Authors:  Claudio Tripodo; Emilio Iannitto; Ada Maria Florena; Carlo Ennio Pucillo; Pier Paolo Piccaluga; Vito Franco; Stefano Aldo Pileri
Journal:  Nat Rev Clin Oncol       Date:  2009-11-10       Impact factor: 66.675

Review 6.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

Review 7.  Complex role of γδ T-cell-derived cytokines and growth factors in cancer.

Authors:  Andrew G Ramstead; Mark A Jutila
Journal:  J Interferon Cytokine Res       Date:  2012-10-18       Impact factor: 2.607

Review 8.  Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration.

Authors:  L Wang; Y Zhao; S Shi
Journal:  J Dent Res       Date:  2012-09-17       Impact factor: 6.116

9.  Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.

Authors:  Alessandra Musso; Silvia Catellani; Paolo Canevali; Sara Tavella; Roberta Venè; Silvia Boero; Ivana Pierri; Marco Gobbi; Annalisa Kunkl; Jean-Louis Ravetti; Maria Raffaella Zocchi; Alessandro Poggi
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

Review 10.  How stem cells speak with host immune cells in inflammatory brain diseases.

Authors:  Stefano Pluchino; Chiara Cossetti
Journal:  Glia       Date:  2013-04-30       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.